Grant: Knowledge Synthesis Grant
University of Ottawa
$100,000.00
Comparative Effectiveness of Second-Line Antiretroviral Therapies for the Treatment of Drug Experienced HIV Infection: A Bayesian Network Meta-Analysis
EF 2013-14
Résumé
HIV/AIDS remains one of the leading infectious causes of mortality in Africa. Thanks to billions of dollars of international donor support and concerted efforts by national governments over the last decade, tremendous progress has been achieved in scaling up access to treatment for HIV/AIDS. Today over 10 million people are receiving antiretroviral therapy in low- and middle-income settings, representing some 61% of people in need. Such a rapid scale up in treatment access in some of the poorest parts of the world has largely been possibly because of the availability of simple first-line triple-drug therapy.
A major challenge today facing HIV/AIDS treatment programmes globally is the need to effective second-line treatment for people failing their initial drug regimen. Conservative estimates suggest that some 3 million people in low-and middle-income settings will have been on treatment for at least five years. Patients fail their first course of treatment for a range of reasons, including sub-optimal adherence, infection with strains of virus resistant to certain drugs, genetic factors, or interactions with medicines taken for concommitant infections.
Accurate diagnosis of treatment failure relies on viral load measurements that until recently has not been possible in most of Africa, but in settings where viral load monitoring is available, such as South Africa, around 15% of patients are found to need to switch to second line therapy within 5 years. Thus it can be estimated that at least half a million people in Africa need second-line treatment. The World Health Organization (WHO), major donors including the Global Fund and PEPFAR, and major implementing agencies such as Médecins Sans Frontières, have all placed a high priority on improving access to viral load. It can be predicted that the need for second-line treatment will grow rapidly in the coming years.
In most high-burden countries in Africa, there are no treatment options beyond second-line therapy, and for patients failing first line treatment, second-line drugs represent their last chance of effective treatment.There is thus an urgent medical and public health need to ensure that second-line therapy is as potent, robust and tolerable as possible both to reduce mortality among patients failing first-line therapy and to reduce the public health risk of transmitted drug resistance. However, while current global and national guideline recommendations for first-line therapy are based on high quality evidence from several randomized trials, the evidence base for second-line therapy has not been adequately assessed: recommendations for seocnd-line therapy published by WHO in June 2013 are based on low- to very-low quality evidence.
Our proposal aims to address this evidence gap by undertaking a network meta-analysis to compare the relative efficacy and safety of the currently approved newer antiretroviral agents when used for second-line regimens. This will be the most comprehensive assessment of the evidence-base to date. The evidence generated by this review will directly inform global and national treatment guidelines, that in turn can be expected to increase survival and life-expectancy, and reduce the risk of drug resistance.
Programme
Knowledge Synthesis Grant
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
295229
Name
Mills Edward J
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Health systems / services
Prcname2
Knowledge Synthesis Grant
Projecttitle
Comparative Effectiveness of Second-Line Antiretroviral Therapies for the Treatment of Drug Experienced HIV Infection: A Bayesian Network Meta-Analysis
Programtype2
Operating Grants
Orgnameinp2
University of Ottawa
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Knowledge Synthesis Grant
Keyworddelim
Antiretroviral Therapy; Drug Efficacy; Drug Safety; Hiv; Network Meta-Analysis
Abstract
<html>
<body>HIV/AIDS remains one of the leading infectious causes of mortality in Africa. Thanks to billions of dollars of international donor support and concerted efforts by national governments over the last decade, tremendous progress has been achieved in scaling up access to treatment for HIV/AIDS. Today over 10 million people are receiving antiretroviral therapy in low- and middle-income settings, representing some 61% of people in need. Such a rapid scale up in treatment access in some of the poorest parts of the world has largely been possibly because of the availability of simple first-line triple-drug therapy.<br>
<br> A major challenge today facing HIV/AIDS treatment programmes globally is the need to effective second-line treatment for people failing their initial drug regimen. Conservative estimates suggest that some 3 million people in low-and middle-income settings will have been on treatment for at least five years. Patients fail their first course of treatment for a range of reasons, including sub-optimal adherence, infection with strains of virus resistant to certain drugs, genetic factors, or interactions with medicines taken for concommitant infections. <br>
<br> Accurate diagnosis of treatment failure relies on viral load measurements that until recently has not been possible in most of Africa, but in settings where viral load monitoring is available, such as South Africa, around 15% of patients are found to need to switch to second line therapy within 5 years. Thus it can be estimated that at least half a million people in Africa need second-line treatment. The World Health Organization (WHO), major donors including the Global Fund and PEPFAR, and major implementing agencies such as Médecins Sans Frontières, have all placed a high priority on improving access to viral load. It can be predicted that the need for second-line treatment will grow rapidly in the coming years.<br>
<br> In most high-burden countries in Africa, there are no treatment options beyond second-line therapy, and for patients failing first line treatment, second-line drugs represent their last chance of effective treatment.There is thus an urgent medical and public health need to ensure that second-line therapy is as potent, robust and tolerable as possible both to reduce mortality among patients failing first-line therapy and to reduce the public health risk of transmitted drug resistance. However, while current global and national guideline recommendations for first-line therapy are based on high quality evidence from several randomized trials, the evidence base for second-line therapy has not been adequately assessed: recommendations for seocnd-line therapy published by WHO in June 2013 are based on low- to very-low quality evidence.<br>
<br>
<strong>Our proposal aims to address this evidence gap by undertaking a network meta-analysis to compare</strong> <strong>the relative efficacy and safety of the currently approved newer antiretroviral agents when used for second-line regimens.</strong> This will be the most comprehensive assessment of the evidence-base to date. The evidence generated by this review will directly inform global and national treatment guidelines, that in turn can be expected to increase survival and life-expectancy, and reduce the risk of drug resistance.</body>
</html>
Competitiondate
201310
Approvedterm2
1 yr 0 mth
Pinamesdelim
Mills, Edward J; Ford, Nathan
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~